{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:35:09Z","timestamp":1768005309881,"version":"3.49.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,7,9]],"date-time":"2015-07-09T00:00:00Z","timestamp":1436400000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s00432-015-2014-2","type":"journal-article","created":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T04:56:14Z","timestamp":1436331374000},"page":"2205-2212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma"],"prefix":"10.1007","volume":"141","author":[{"name":"German Refractory Myeloma Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"St\u00f6hr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic Carsten","family":"Schmeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard Christopher","family":"Schmeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo G. H.","family":"Schmidt-Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,9]]},"reference":[{"issue":"2","key":"2014_CR1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","volume":"22","author":"KC Anderson","year":"2008","unstructured":"Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P (2008) Clinically relevant end points and new drug approvals for myeloma. Leukemia 22(2):231\u2013239. doi: 10.1038\/sj.leu.2405016","journal-title":"Leukemia"},{"issue":"3","key":"2014_CR2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/bjh.12129","volume":"160","author":"JR Berenson","year":"2013","unstructured":"Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS et al (2013) Phase I\/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 160(3):321\u2013330. doi: 10.1111\/bjh.12129","journal-title":"Br J Haematol"},{"issue":"9","key":"2014_CR3","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau J-L, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467\u20131473. doi: 10.1038\/sj.leu.2404284","journal-title":"Leukemia"},{"issue":"4","key":"2014_CR4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2141.2011.08887.x","volume":"156","author":"E Grey-Davies","year":"2012","unstructured":"Grey-Davies E, Bosworth JL, Boyd KD, Ebdon C, Saso R, Chitnavis D et al (2012) Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. Br J Haematol 156(4):552\u2013555. doi: 10.1111\/j.1365-2141.2011.08887.x","journal-title":"Br J Haematol"},{"issue":"3","key":"2014_CR5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/cncr.24057","volume":"115","author":"M Kalaycio","year":"2009","unstructured":"Kalaycio M (2009) Bendamustine: a new look at an old drug. Cancer 115(3):473\u2013479. doi: 10.1002\/cncr.24057","journal-title":"Cancer"},{"issue":"20","key":"2014_CR6","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/blood-2011-12-395715","volume":"119","author":"S Lentzsch","year":"2012","unstructured":"Lentzsch S, O\u2019Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL et al (2012) Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1\/2 open-label, dose escalation study. Blood 119(20):4608\u20134613. doi: 10.1182\/blood-2011-12-395715","journal-title":"Blood"},{"issue":"7","key":"2014_CR7","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1182\/blood-2013-08-521468","volume":"123","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N et al (2014) Bendamustine\u2013bortezomib\u2013dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 123(7):985\u2013991. doi: 10.1182\/blood-2013-08-521468","journal-title":"Blood"},{"issue":"1","key":"2014_CR8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2047-783X-15-1-13","volume":"15","author":"M Michael","year":"2010","unstructured":"Michael M, Bruns I, B\u00f6lke E, Zohren F, Czibere A, Safaian NN et al (2010) Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 15(1):13\u201319","journal-title":"Eur J Med Res"},{"issue":"1","key":"2014_CR9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2008.07303.x","volume":"143","author":"R Niesvizky","year":"2008","unstructured":"Niesvizky R, Richardson PG, Rajkumar SV, Coleman M, Rosi\u00f1ol L, Sonneveld P et al (2008) The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol 143(1):46\u201353. doi: 10.1111\/j.1365-2141.2008.07303.x","journal-title":"Br J Haematol"},{"issue":"11","key":"2014_CR10","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1038\/bcj.2013.58","volume":"3","author":"M Offidani","year":"2013","unstructured":"Offidani M, Corvatta L, Maracci L, Liberati AM, Ballanti S, Attolico I et al (2013) Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J 3(11):e162. doi: 10.1038\/bcj.2013.58","journal-title":"Blood Cancer J"},{"issue":"4","key":"2014_CR11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","volume":"132","author":"W P\u00f6nisch","year":"2006","unstructured":"P\u00f6nisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G et al (2006) Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone\u2014a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 132(4):205\u2013212. doi: 10.1007\/s00432-005-0074-4","journal-title":"J Cancer Res Clin Oncol"},{"key":"2014_CR12","author":"W P\u00f6nisch","year":"2013","unstructured":"P\u00f6nisch W, Heyn S, Beck J, Wagner I, Mohren M, Hoffmann FA et al (2013) Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO-#077. Br J Haematol. doi: 10.1111\/bjh.12361","journal-title":"Br J Haematol"},{"issue":"2","key":"2014_CR13","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.3324\/haematol.2014.110890","volume":"100","author":"P Rodon","year":"2015","unstructured":"Rodon P, Hulin C, Pegourie B, Tiab M, Anglaret B, Benboubker L et al (2015) Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. Haematologica 100(2):e56\u2013e59. doi: 10.3324\/haematol.2014.110890","journal-title":"Haematologica"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-2014-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-015-2014-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-2014-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T18:40:54Z","timestamp":1559068854000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-015-2014-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,9]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["2014"],"URL":"https:\/\/doi.org\/10.1007\/s00432-015-2014-2","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,9]]}}}